Literature DB >> 10348227

Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives.

R Price1, M van Vugt, L Phaipun, C Luxemburger, J Simpson, R McGready, F ter Kuile, A Kham, T Chongsuphajaisiddhi, N J White, F Nosten.   

Abstract

In prospective studies of acute uncomplicated, multidrug-resistant falciparum malaria on the western border of Thailand, the oral artemisinin derivatives were used alone in the treatment of 836 patients (artesunate 630, artemether 206), were combined with mefloquine (15-25 mg base/kg) in 2,826 patients, and mefloquine alone was used in 1,303 patients. The combined regimens of mefloquine plus an artemisinin derivative were associated with more side effects than those with an artemisinin derivative alone; acute nausea (31% versus 16%), vomiting (24% versus 11%), anorexia (51% versus 34%), and dizziness (47% versus 15%) (P < 0.001). Oral artesunate and artemether alone were very well tolerated. There was no difference in the incidence of possible adverse effects between the two drugs, and no evidence that either derivative caused allergic reactions, neurologic or psychiatric reactions, or cardiovascular or dermatologic toxicity. Blackwater fever occurred in three patients treated with mefloquine plus artesunate regimens. Oral artesunate and artemether are safe and well tolerated antimalarial drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348227     DOI: 10.4269/ajtmh.1999.60.547

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  61 in total

Review 1.  Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials.

Authors:  Jürg Utzinger; Jennifer Keiser; Xiao Shuhua; Marcel Tanner; Burton H Singer
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

2.  Reaction of artemisinin with haemoglobin: implications for antimalarial activity.

Authors:  Rangiah Kannan; Krishan Kumar; Dinkar Sahal; Shrikant Kukreti; Virander S Chauhan
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

Review 3.  Resurgent malaria at the millennium: control strategies in crisis.

Authors:  J K Baird
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

4.  Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval.

Authors:  Jessica Manning; Pattaraporn Vanachayangkul; Chanthap Lon; Michele Spring; Mary So; Darapiseth Sea; Youry Se; Sok Somethy; Sut-Thang Phann; Soklyda Chann; Sabaithip Sriwichai; Nillawan Buathong; Worachet Kuntawunginn; Mashamon Mitprasat; Raveewan Siripokasupkul; Paktiya Teja-Isavadharm; Eugene Soh; Ans Timmermans; Charlotte Lanteri; Jaranit Kaewkungwal; Montida Auayporn; Douglas Tang; Char Meng Chour; Satharath Prom; Mark Haigney; Louis Cantilena; David Saunders
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

5.  Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria.

Authors:  Ann K Miller; Nibedita Bandyopadhyay; Daniel G Wootton; Stephan Duparc; Paula L Kirby; Peter A Winstanley; Stephen A Ward
Journal:  Eur J Clin Pharmacol       Date:  2009-06-11       Impact factor: 2.953

6.  Tolerability and efficacy of a pediatric granule formulation of artesunate-mefloquine in young children from Cameroon with uncomplicated falciparum malaria.

Authors:  Félix Tietche; David Chelo; Njiki Kinkela Mina Ntoto; Florence Minjiwa Djoukoue; Christoph Hatz; Sarabel Frey; Adrian Frentzel; Sonja Trapp; Roland Zielonka; Edgar A Mueller
Journal:  Am J Trop Med Hyg       Date:  2010-06       Impact factor: 2.345

7.  Randomized control trial of quinine and artesunate in complicated malaria.

Authors:  Anil Kumar Mohanty; B K Rath; R Mohanty; A K Samal; K Mishra
Journal:  Indian J Pediatr       Date:  2004-04       Impact factor: 1.967

8.  Artesunate, an anti-malarial drug, has a potential to inhibit HCV replication.

Authors:  Rongjuan Dai; Xinqiang Xiao; Feng Peng; Mingming Li; Guozhong Gong
Journal:  Virus Genes       Date:  2016-01-06       Impact factor: 2.332

9.  The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria.

Authors:  Michael T Ambler; Lilly M Dubowitz; Ratree Arunjerdja; Eh Paw Hla; Kyaw Lay Thwai; Jacher Viladpainguen; Pratap Singhasivanon; Christine Luxemburger; François Nosten; Rose McGready
Journal:  Malar J       Date:  2009-09-02       Impact factor: 2.979

10.  Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria?

Authors:  Richard J Maude; Katherine Plewes; M Abul Faiz; Josh Hanson; Prakaykaew Charunwatthana; Sue J Lee; Joel Tärning; Emran Bin Yunus; M Gofranul Hoque; Mahatab Uddin Hasan; Amir Hossain; Niklas Lindegardh; Nicholas P J Day; Nicholas J White; Arjen M Dondorp
Journal:  Am J Trop Med Hyg       Date:  2009-01       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.